In 2015, there was an increase of 11.2% in the number of reported dengue cases from the previous year. Because most children and young adults spend more time outdoors, they are more likely to be infected. Here’s how you can protect your family:
UPDATE ON DENGUE VACCINE
- Dengvaxia® (CYD-TDV) is the only licensed dengue vaccine.
- Dengvaxia® has been approved for marketing in Mexico, El Salvador, Brazil, Singapore, the Philippines and Costa Rica.
- A South American based vaccine, TV003, is currently in phase III.
- Phase II trial for a dengue vaccine candidate, DENVax, is underway.
- Three additional dengue vaccine candidates are in clinical development.
Vaccine Efficacy in Clinical Trials
- Manufacturers of Dengvaxia® claim it prevents 8 out of 10 hospitalizations and 9 out of 10 severe cases and is 60.8% efficacious against all four dengue serotypes.
- In one small study, TV003 showed it could protect all 21 participating volunteers from the Dengue-2 virus.
- WHO recommends that countries should consider introduction of the dengue vaccine CYD-TDV only in geographic settings (national or subnational) where epidemiological data indicate a high burden of disease.
An educational contribution by Malaysian Paediatric Association.
Comments